Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of one systematic review(s)/meta-analysis(es). ^[1]
• In patients with acute myeloid leukemia (AML) ineligible for first-line induction chemotherapy, the combination of targeted therapies such as venetoclax and ivosidenib with hypomethylating agents (HMAs) resulted in better overall survival (OS) with hazard ratios (HRs) ranging from 0.44 to 0.66, and improved event-free survival (EFS) with HRs ranging from 0.33 to 0.63, compared to other agents.
• No significant difference in event-free survival (EFS) or overall survival (OS) was observed between intermittent PEG-asparaginase (eight doses) and continuous PEG-asparaginase (15 doses) in non-high-risk acute lymphoblastic leukemia (ALL) patients, as well as between low-risk standard treatment with additional PEG-asparaginase (six doses) and standard treatment (two doses), with risk ratios (RR) close to 1.
• The study does not provide specific effectiveness data for glasdegib (Daurismo) but highlights the superior effectiveness of venetoclax and ivosidenib combined with HMAs over other treatments for this patient population.
• No specific effectiveness outcomes were mentioned for different population types or subgroups in the reviewed study.
• The study reports that adverse events (AEs) were more frequent with combination therapies involving venetoclax and ivosidenib compared to control arms, except for the combination of ivosidenib plus azacitidine, which did not show an increase in AEs.
• No specific safety outcomes were provided for glasdegib (Daurismo) in the reviewed studies.
• There is no population type or subgroup information available in the reviewed studies.